Device and method for in-vivo micro-bubble control and imaging

Abstract

The invention discloses a device and method for in-vivo micro-bubble control and imaging. The device comprises a support type in-vivo implanting structure, drug-loading micro-bubbles, a control arraytransducer unit and an imaging array transducer unit. Drug particles are loaded on the surfaces of the micro-bubbles or in the micro-bubbles, the drug-loading micro-bubbles are captured and gathered by the support type in-vivo implanting structure under the action of a local-area sound field, the micro-bubbles are broken by changing the ultrasonic intensity, and the drug particles are released. The control array transducer unit is used for transmitting power ultrasonic to excite the support type in-vivo implanting structure to vibrate and capture the drug-loading micro-bubbles in blood vessels. The imaging array transducer unit is used for emitting pulse waves, receiving echo signals from different positions, and imaging the micro-bubbles, the support type in-vivo implanting structure andtissue structures. According to the device, the resonance sound field generated by the support type in-vivo implanting structure is utilized, so that the micro-bubble aggregation in the blood vesselsis controlled; an ultrasonic transducer used for imaging is additionally arranged, and the micro-bubble control effect can be observed in real time.

Description

technical field [0001] The invention belongs to the technical field of ultrasonic drug delivery, and in particular relates to a device and method for manipulation and imaging of microbubbles in vivo. Background technique [0002] The statements in this section merely provide background information related to the present invention and do not necessarily constitute prior art. [0003] For the treatment of diseases, it is often necessary to implant artificial prostheses in the human body, such as artificial skulls, artificial joints, artificial bones, and various intracavitary implants, such as vascular stents, tracheal stents, esophageal stents, urethral stents, etc. For many diseases, these implants cannot cure the primary disease. In order to continuously intervene in the disease process or maintain the patency of the implant in the cavity, it is necessary to continue to deliver drugs that interfere with the disease process to the implant in subsequent treatments. the impla...

AI Technical Summary

Problems solved by technology

For example, arterial stenosis caused by atherosclerosis, although the use of intravascular stents can effectively solve the problem of stenosis of the lumen, but because atherosclerosis cannot be cured only by the support of stents, it is accompanied by stent implantation. In-stent restenosis makes maintaining stent patency a new problem and challenge

[0004] Although there is currently a drug-eluting stent technology to slow down in-stent restenosis, this technology has caused new problems: the eluted drug is an anticancer drug such as sirolimus, which leads to delayed healing of the vascular endothelium and promotes stent restenosis. The risk of internal thrombosis; in order to reduce this problem, two or more antiplatelet drugs need to be taken orally, which leads to an increased risk of systemic bleeding, especially bleeding in some parts is often fatal; at the same time, there are studies It was confirmed that these drugs eluted from the stent can be locally enriched in the myocardium, causing cardiotoxicity

Therefore, direct acoustic radiation force-trapping manipulation of nanoscale drug particles and ultrasound imaging of these particles are extremely difficult

Images